Revive Therapeutics Ltd. announced that Dr. Lee S. Simon, M.D. will join the Company as senior clinical and regulatory affairs advisor for the Company. Dr. Simon is presently a Principal in SDG LLC. and has extensive experience with the U.S. FDA drug approval process having served as the FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products (2001-2003) and served prior to that on multiple FDA advisory committees.

He has been a clinical Rheumatologist for over 25 year and has extensive experience in drug development as a senior investigator for Celebrex® (celecoxib) and led the team to obtain the FDA approval of Krystexxa® (pegloticase) for the treatment of chronic treatment failure gout in the U.S. Dr. Simon was a senior consultant to Pharmacia/Searle on COX-2 development and he also served as Head regulatory consultant to Leerink Swann/Medacorp in Boston, MA. Dr. Simon joins Revive as the Company focuses on advancing its lead product, REV-002 (Bucillamine), which is being developed for the treatment of acute gout flares.